Overview

A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-11-01

Target enrollment:

Participant gender:

Summary

This study is a multicenter, double-masked, vehicle-controlled, randomized, parallel group study designed to evaluate the treatment of abnormal meibomian gland function and associated symptoms of DED using either AZR-MD-001 0.5% ophthalmic ointment or its vehicle. Study drug (either AZR-MD-001 or vehicle) will be dosed twice-weekly at bedtime for up to 12 months.

Phase:

PHASE3

Details

Lead Sponsor:

Azura Ophthalmics

Collaborator:

ORA, Inc.